Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $273,735.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 38,500 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $7.11, for a total value of $273,735.00. Following the completion of the sale, the insider owned 4,106,452 shares in the company, valued at approximately $29,196,873.72. The trade was a 0.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Wednesday, September 9th, Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.13, for a total value of $205,607.81.
• On Tuesday, September 8th, Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.41, for a total value of $1,426,425.00.
• On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total value of $231,325.71.
• On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.19, for a total value of $180,691.89.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total transaction of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total transaction of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total transaction of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Stock Up 5.9%

NASDAQ TRDA opened at $6.80 on Friday. The company’s 50 day moving average is $7.00 and its 200-day moving average is $9.04. Entrada Therapeutics, Inc. has a 12-month low of $5.02 and a 12-month high of $16.45. The firm has a market cap of $264.79 million, a P/E ratio of -1.72 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. Equities analysts expect that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TRDA. State of Wyoming purchased a new position in shares of Entrada Therapeutics during the 2nd quarter valued at $37,000. Russell Investments Group Ltd. raised its position in shares of Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after buying an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics during the second quarter valued at $68,000. Jain Global LLC bought a new stake in Entrada Therapeutics during the third quarter valued at $69,000. Finally, IHT Wealth Management LLC purchased a new position in Entrada Therapeutics during the second quarter worth about $72,000. 86.39% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TRDA has been the subject of several recent research reports. Weiss Ratings upgraded Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Roth Capital reissued a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Wall Street Zen upgraded Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 5th. Finally, Guggenheim reduced their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.75.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.